請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38060
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李財坤(Tsai-Kun Li) | |
dc.contributor.author | Jia-Rong Fan | en |
dc.contributor.author | 范嘉榕 | zh_TW |
dc.date.accessioned | 2021-06-13T15:59:23Z | - |
dc.date.available | 2011-08-13 | |
dc.date.copyright | 2008-08-13 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-05-08 | |
dc.identifier.citation | [1] J.D. Watson and F.H. Crick. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid, Nature 171 (1953) 737-738.
[2] L.F. Liu and J.C. Wang. Supercoiling of the DNA template during transcription, Proc Natl Acad Sci U S A 84 (1987) 7024-7027. [3] F.B. Fuller. The writhing number of a space curve, Proc Natl Acad Sci U S A 68 (1971) 815-819. [4] F.B. Fuller. Decomposition of the linking number of a closed ribbon: A problem from molecular biology, Proc Natl Acad Sci U S A 75 (1978) 3557-3561. [5] J.C. Wang. Cellular roles of DNA topoisomerases: a molecular perspective, Nat Rev Mol Cell Biol 3 (2002) 430-440. [6] Y. Liu, V. Bondarenko, A. Ninfa and V.M. Studitsky. DNA supercoiling allows enhancer action over a large distance, Proc Natl Acad Sci U S A 98 (2001) 14883-14888. [7] J.C. Wang. Interaction between DNA and an Escherichia coli protein omega, J Mol Biol 55 (1971) 523-533. [8] M. Gellert, K. Mizuuchi, M.H. O'Dea and H.A. Nash. DNA gyrase: an enzyme that introduces superhelical turns into DNA, Proc Natl Acad Sci U S A 73 (1976) 3872-3876. [9] P. D'Arpa, P.S. Machlin, H. Ratrie, 3rd, N.F. Rothfield, D.W. Cleveland and W.C. Earnshaw. cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment, Proc Natl Acad Sci U S A 85 (1988) 2543-2547. [10] R. Hanai, P.R. Caron and J.C. Wang. Human TOP3: a single-copy gene encoding DNA topoisomerase III, Proc Natl Acad Sci U S A 93 (1996) 3653-3657. [11] S.W. Ng, Y. Liu, K.T. Hasselblatt, S.C. Mok and R.S. Berkowitz. A new human topoisomerase III that interacts with SGS1 protein, Nucleic Acids Res 27 (1999) 993-1000. [12] S.G. Morham, K.D. Kluckman, N. Voulomanos and O. Smithies. Targeted disruption of the mouse topoisomerase I gene by camptothecin selection, Mol Cell Biol 16 (1996) 6804-6809. [13] S.D. Baker, R.M. Wadkins, C.F. Stewart, W.T. Beck and M.K. Danks. Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy, Cytometry 19 (1995) 134-145. [14] J.B. Leppard and J.J. Champoux. Human DNA topoisomerase I: relaxation, roles, and damage control, Chromosoma 114 (2005) 75-85. [15] K.M. Hannan, R.D. Hannan and L.I. Rothblum. Transcription by RNA polymerase I, Front Biosci 3 (1998) d376-398. [16] J.J. Champoux. DNA topoisomerases: structure, function, and mechanism, Annu Rev Biochem 70 (2001) 369-413. [17] M. Tsai-Pflugfelder, L.F. Liu, A.A. Liu, K.M. Tewey, J. Whang-Peng, T. Knutsen, K. Huebner, C.M. Croce and J.C. Wang. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22, Proc Natl Acad Sci U S A 85 (1988) 7177-7181. [18] J.R. Jenkins, P. Ayton, T. Jones, S.L. Davies, D.L. Simmons, A.L. Harris, D. Sheer and I.D. Hickson. Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24, Nucleic Acids Res 20 (1992) 5587-5592. [19] C.A. Austin and K.L. Marsh. Eukaryotic DNA topoisomerase II beta, Bioessays 20 (1998) 215-226. [20] C.A. Austin, J.H. Sng, S. Patel and L.M. Fisher. Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases, Biochim Biophys Acta 1172 (1993) 283-291. [21] P.E. Warburton and W.C. Earnshaw. Untangling the role of DNA topoisomerase II in mitotic chromosome structure and function, Bioessays 19 (1997) 97-99. [22] N. Chaly, X. Chen, J. Dentry and D.L. Brown. Organization of DNA topoisomerase II isotypes during the cell cycle of human lymphocytes and HeLa cells, Chromosome Res 4 (1996) 457-466. [23] S. Taagepera, P.N. Rao, F.H. Drake and G.J. Gorbsky. DNA topoisomerase II alpha is the major chromosome protein recognized by the mitotic phosphoprotein antibody MPM-2, Proc Natl Acad Sci U S A 90 (1993) 8407-8411. [24] X. Yang, W. Li, E.D. Prescott, S.J. Burden and J.C. Wang. DNA topoisomerase IIbeta and neural development, Science 287 (2000) 131-134. [25] J.C. Wang. DNA topoisomerases, Annu Rev Biochem 65 (1996) 635-692. [26] M.F. Christman, F.S. Dietrich and G.R. Fink. Mitotic recombination in the rDNA of S. cerevisiae is suppressed by the combined action of DNA topoisomerases I and II, Cell 55 (1988) 413-425. [27] S. Gangloff, M.R. Lieber and R. Rothstein. Transcription, topoisomerases and recombination, Experientia 50 (1994) 261-269. [28] R.A. Kim, P.R. Caron and J.C. Wang. Effects of yeast DNA topoisomerase III on telomere structure, Proc Natl Acad Sci U S A 92 (1995) 2667-2671. [29] J.L. Nitiss. Investigating the biological functions of DNA topoisomerases in eukaryotic cells, Biochim Biophys Acta 1400 (1998) 63-81. [30] T. Goto and J.C. Wang. Yeast DNA topoisomerase II is encoded by a single-copy, essential gene, Cell 36 (1984) 1073-1080. [31] T.Z. Win, A. Goodwin, I.D. Hickson, C.J. Norbury and S.W. Wang. Requirement for Schizosaccharomyces pombe Top3 in the maintenance of chromosome integrity, J Cell Sci 117 (2004) 4769-4778. [32] A. Goodwin, S.W. Wang, T. Toda, C. Norbury and I.D. Hickson. Topoisomerase III is essential for accurate nuclear division in Schizosaccharomyces pombe, Nucleic Acids Res 27 (1999) 4050-4058. [33] K.Y. Kwan, P.B. Moens and J.C. Wang. Infertility and aneuploidy in mice lacking a type IA DNA topoisomerase III beta, Proc Natl Acad Sci U S A 100 (2003) 2526-2531. [34] M. Seki, T. Nakagawa, T. Seki, G. Kato, S. Tada, Y. Takahashi, A. Yoshimura, T. Kobayashi, A. Aoki, M. Otsuki, F.A. Habermann, H. Tanabe, Y. Ishii and T. Enomoto. Bloom helicase and DNA topoisomerase IIIalpha are involved in the dissolution of sister chromatids, Mol Cell Biol 26 (2006) 6299-6307. [35] C.S. Downes, D.J. Clarke, A.M. Mullinger, J.F. Gimenez-Abian, A.M. Creighton and R.T. Johnson. A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells, Nature 372 (1994) 467-470. [36] P.B. Deming, C.A. Cistulli, H. Zhao, P.R. Graves, H. Piwnica-Worms, R.S. Paules, C.S. Downes and W.K. Kaufmann. The human decatenation checkpoint, Proc Natl Acad Sci U S A 98 (2001) 12044-12049. [37] P.B. Deming, K.G. Flores, C.S. Downes, R.S. Paules and W.K. Kaufmann. ATR enforces the topoisomerase II-dependent G2 checkpoint through inhibition of Plk1 kinase, J Biol Chem 277 (2002) 36832-36838. [38] A. Franchitto, J. Oshima and P. Pichierri. The G2-phase decatenation checkpoint is defective in Werner syndrome cells, Cancer Res 63 (2003) 3289-3295. [39] R.K. Chakraverty, J.M. Kearsey, T.J. Oakley, M. Grenon, M.A. de La Torre Ruiz, N.F. Lowndes and I.D. Hickson. Topoisomerase III acts upstream of Rad53p in the S-phase DNA damage checkpoint, Mol Cell Biol 21 (2001) 7150-7162. [40] K.R. Hande. Clinical applications of anticancer drugs targeted to topoisomerase II, Biochim Biophys Acta 1400 (1998) 173-184. [41] A. Montecucco and G. Biamonti. Cellular response to etoposide treatment, Cancer Lett (2006). [42] D. Hanahan and R.A. Weinberg. The hallmarks of cancer, Cell 100 (2000) 57-70. [43] H. Rajagopalan, M.A. Nowak, B. Vogelstein and C. Lengauer. The significance of unstable chromosomes in colorectal cancer, Nat Rev Cancer 3 (2003) 695-701. [44] F. Michor, Y. Iwasa, B. Vogelstein, C. Lengauer and M.A. Nowak. Can chromosomal instability initiate tumorigenesis?, Semin Cancer Biol 15 (2005) 43-49. [45] C. Lengauer, K.W. Kinzler and B. Vogelstein. Genetic instabilities in human cancers, Nature 396 (1998) 643-649. [46] T. Hirano. Chromosome cohesion, condensation, and separation, Annu Rev Biochem 69 (2000) 115-144. [47] T. Uemura, H. Ohkura, Y. Adachi, K. Morino, K. Shiozaki and M. Yanagida. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe, Cell 50 (1987) 917-925. [48] Y. Adachi, M. Luke and U.K. Laemmli. Chromosome assembly in vitro: topoisomerase II is required for condensation, Cell 64 (1991) 137-148. [49] E.R. Wood and W.C. Earnshaw. Mitotic chromatin condensation in vitro using somatic cell extracts and nuclei with variable levels of endogenous topoisomerase II, J Cell Biol 111 (1990) 2839-2850. [50] Z. Lou, K. Minter-Dykhouse and J. Chen. BRCA1 participates in DNA decatenation, Nat Struct Mol Biol 12 (2005) 589-593. [51] C.A. Andrews, A.C. Vas, B. Meier, J.F. Gimenez-Abian, L.A. Diaz-Martinez, J. Green, S.L. Erickson, K.E. Vanderwaal, W.S. Hsu and D.J. Clarke. A mitotic topoisomerase II checkpoint in budding yeast is required for genome stability but acts independently of Pds1/securin, Genes Dev 20 (2006) 1162-1174. [52] W.K. Kaufmann, C.B. Campbell, D.A. Simpson, P.B. Deming, L. Filatov, D.A. Galloway, X.J. Zhao, A.M. Creighton and C.S. Downes. Degradation of ATM-independent decatenation checkpoint function in human cells is secondary to inactivation of p53 and correlated with chromosomal destabilization, Cell Cycle 1 (2002) 210-219. [53] S. Murakami, M. Yanagida and O. Niwa. A large circular minichromosome of Schizosaccharomyces pombe requires a high dose of type II DNA topoisomerase for its stabilization, Mol Gen Genet 246 (1995) 671-679. [54] R.J. DiGate and K.J. Marians. Identification of a potent decatenating enzyme from Escherichia coli, J Biol Chem 263 (1988) 13366-13373. [55] F.G. Harmon, R.J. DiGate and S.C. Kowalczykowski. RecQ helicase and topoisomerase III comprise a novel DNA strand passage function: a conserved mechanism for control of DNA recombination, Mol Cell 3 (1999) 611-620. [56] H.W. Mankouri and I.D. Hickson. Top3 processes recombination intermediates and modulates checkpoint activity after DNA damage, Mol Biol Cell 17 (2006) 4473-4483. [57] H.J. Tsai, W.H. Huang, T.K. Li, Y.L. Tsai, K.J. Wu, S.F. Tseng and S.C. Teng. Involvement of topoisomerase III in telomere-telomere recombination, J Biol Chem 281 (2006) 13717-13723. [58] Q. Zhu, P. Pongpech and R.J. DiGate. Type I topoisomerase activity is required for proper chromosomal segregation in Escherichia coli, Proc Natl Acad Sci U S A 98 (2001) 9766-9771. [59] S. Gangloff, J.P. McDonald, C. Bendixen, L. Arthur and R. Rothstein. The yeast type I topoisomerase Top3 interacts with Sgs1, a DNA helicase homolog: a potential eukaryotic reverse gyrase, Mol Cell Biol 14 (1994) 8391-8398. [60] J.W. Wallis, G. Chrebet, G. Brodsky, M. Rolfe and R. Rothstein. A hyper-recombination mutation in S. cerevisiae identifies a novel eukaryotic topoisomerase, Cell 58 (1989) 409-419. [61] W. Li and J.C. Wang. Mammalian DNA topoisomerase IIIalpha is essential in early embryogenesis, Proc Natl Acad Sci U S A 95 (1998) 1010-1013. [62] E. Fritz, S.H. Elsea, P.I. Patel and M.S. Meyn. Overexpression of a truncated human topoisomerase III partially corrects multiple aspects of the ataxia-telangiectasia phenotype, Proc Natl Acad Sci U S A 94 (1997) 4538-4542. [63] I.D. Hickson. RecQ helicases: caretakers of the genome, Nat Rev Cancer 3 (2003) 169-178. [64] V.A. Rao, A.M. Fan, L. Meng, C.F. Doe, P.S. North, I.D. Hickson and Y. Pommier. Phosphorylation of BLM, dissociation from topoisomerase IIIalpha, and colocalization with gamma-H2AX after topoisomerase I-induced replication damage, Mol Cell Biol 25 (2005) 8925-8937. [65] M. Amor-Gueret. Bloom syndrome, genomic instability and cancer: the SOS-like hypothesis, Cancer Lett 236 (2006) 1-12. [66] Y. Hu, S. Raynard, M.G. Sehorn, X. Lu, W. Bussen, L. Zheng, J.M. Stark, E.L. Barnes, P. Chi, P. Janscak, M. Jasin, H. Vogel, P. Sung and G. Luo. RECQL5/Recql5 helicase regulates homologous recombination and suppresses tumor formation via disruption of Rad51 presynaptic filaments, Genes Dev 21 (2007) 3073-3084. [67] T.J. Oakley and I.D. Hickson. Defending genome integrity during S-phase: putative roles for RecQ helicases and topoisomerase III, DNA Repair (Amst) 1 (2002) 175-207. [68] T.M. Bryan, A. Englezou, L. Dalla-Pozza, M.A. Dunham and R.R. Reddel. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines, Nat Med 3 (1997) 1271-1274. [69] T.M. Bryan, L. Marusic, S. Bacchetti, M. Namba and R.R. Reddel. The telomere lengthening mechanism in telomerase-negative immortal human cells does not involve the telomerase RNA subunit, Hum Mol Genet 6 (1997) 921-926. [70] R.R. Reddel, T.M. Bryan, L.M. Colgin, K.T. Perrem and T.R. Yeager. Alternative lengthening of telomeres in human cells, Radiat Res 155 (2001) 194-200. [71] K.Y. Kwan and J.C. Wang. Mice lacking DNA topoisomerase IIIbeta develop to maturity but show a reduced mean lifespan, Proc Natl Acad Sci U S A 98 (2001) 5717-5721. [72] T. Germe and O. Hyrien. Topoisomerase II-DNA complexes trapped by ICRF-193 perturb chromatin structure, EMBO Rep 6 (2005) 729-735. [73] G.J. Kops, B.A. Weaver and D.W. Cleveland. On the road to cancer: aneuploidy and the mitotic checkpoint, Nat Rev Cancer 5 (2005) 773-785. [74] I. Vivanco and C.L. Sawyers. The phosphatidylinositol 3-Kinase AKT pathway in human cancer, Nat Rev Cancer 2 (2002) 489-501. [75] K.W. Kinzler and B. Vogelstein. Cancer-susceptibility genes. Gatekeepers and caretakers, Nature 386 (1997) 761, 763. [76] N.C. Levitt and I.D. Hickson. Caretaker tumour suppressor genes that defend genome integrity, Trends Mol Med 8 (2002) 179-186. [77] J. Feunteun. Breast cancer and genetic instability: the molecules behind the scenes, Mol Med Today 4 (1998) 263-267. [78] T. Yamashita and T. Nakahata. Current knowledge on the pathophysiology of Fanconi anemia: from genes to phenotypes, Int J Hematol 74 (2001) 33-41. [79] M. Duguet. When helicase and topoisomerase meet!, J Cell Sci 110 ( Pt 12) (1997) 1345-1350. [80] L. Michel, R. Benezra and E. Diaz-Rodriguez. MAD2 dependent mitotic checkpoint defects in tumorigenesis and tumor cell death: a double edged sword, Cell Cycle 3 (2004) 990-992. [81] H. Nakayama. RecQ family helicases: roles as tumor suppressor proteins, Oncogene 21 (2002) 9008-9021. [82] R. Baer and T. Ludwig. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity, Curr Opin Genet Dev 12 (2002) 86-91. [83] T.K. Li and L.F. Liu. Tumor cell death induced by topoisomerase-targeting drugs, Annu Rev Pharmacol Toxicol 41 (2001) 53-77. [84] A. Tomida and T. Tsuruo. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors, Anticancer Drug Des 14 (1999) 169-177. [85] J. Robert and A.K. Larsen. Drug resistance to topoisomerase II inhibitors, Biochimie 80 (1998) 247-254. [86] B.C. Baguley and L.R. Ferguson. Mutagenic properties of topoisomerase-targeted drugs, Biochim Biophys Acta 1400 (1998) 213-222. [87] C.A. Felix. Secondary leukemias induced by topoisomerase-targeted drugs, Biochim Biophys Acta 1400 (1998) 233-255. [88] C.A. Felix, C.P. Kolaris and N. Osheroff. Topoisomerase II and the etiology of chromosomal translocations, DNA Repair (Amst) 5 (2006) 1093-1108. [89] A.R. Mistry, C.A. Felix, R.J. Whitmarsh, A. Mason, A. Reiter, B. Cassinat, A. Parry, C. Walz, J.L. Wiemels, M.R. Segal, L. Ades, I.A. Blair, N. Osheroff, A.J. Peniket, M. Lafage-Pochitaloff, N.C. Cross, C. Chomienne, E. Solomon, P. Fenaux and D. Grimwade. DNA topoisomerase II in therapy-related acute promyelocytic leukemia, N Engl J Med 352 (2005) 1529-1538. [90] R.D. Woessner, M.R. Mattern, C.K. Mirabelli, R.K. Johnson and F.H. Drake. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells, Cell Growth Differ 2 (1991) 209-214. [91] A. Niimi, N. Suka, M. Harata, A. Kikuchi and S. Mizuno. Co-localization of chicken DNA topoisomerase IIalpha, but not beta, with sites of DNA replication and possible involvement of a C-terminal region of alpha through its binding to PCNA, Chromosoma 110 (2001) 102-114. [92] Y.L. Lyu, C.P. Lin, A.M. Azarova, L. Cai, J.C. Wang and L.F. Liu. Role of topoisomerase IIbeta in the expression of developmentally regulated genes, Mol Cell Biol 26 (2006) 7929-7941. [93] K. Tsutsui, K. Sano, A. Kikuchi and A. Tokunaga. Involvement of DNA topoisomerase IIbeta in neuronal differentiation, J Biol Chem 276 (2001) 5769-5778. [94] A.M. Azarova, Y.L. Lyu, C.P. Lin, Y.C. Tsai, J.Y. Lau, J.C. Wang and L.F. Liu. From the Cover: Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies, Proc Natl Acad Sci U S A 104 (2007) 11014-11019. [95] E.L. Baldwin and N. Osheroff. Etoposide, topoisomerase II and cancer, Curr Med Chem Anticancer Agents 5 (2005) 363-372. [96] P.S. Kingma, D.A. Burden and N. Osheroff. Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance, Biochemistry 38 (1999) 3457-3461. [97] R. Ye, A. Bodero, B.B. Zhou, K.K. Khanna, M.F. Lavin and S.P. Lees-Miller. The plant isoflavenoid genistein activates p53 and Chk2 in an ATM-dependent manner, J Biol Chem 276 (2001) 4828-4833. [98] O. Sordet, Q.A. Khan, K.W. Kohn and Y. Pommier. Apoptosis induced by topoisomerase inhibitors, Curr Med Chem Anticancer Agents 3 (2003) 271-290. [99] J.P. Banath and P.L. Olive. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks, Cancer Res 63 (2003) 4347-4350. [100] H. Zhao and H. Piwnica-Worms. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1, Mol Cell Biol 21 (2001) 4129-4139. [101] R.G. Shao, C.X. Cao, H. Zhang, K.W. Kohn, M.S. Wold and Y. Pommier. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes, Embo J 18 (1999) 1397-1406. [102] B. Piret and J. Piette. Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells, Nucleic Acids Res 24 (1996) 4242-4248. [103] N. Adachi, S. Iiizumi, S. So and H. Koyama. Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage, Biochem Biophys Res Commun 318 (2004) 856-861. [104] N. Adachi, H. Suzuki, S. Iiizumi and H. Koyama. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage, J Biol Chem 278 (2003) 35897-35902. [105] A. Adams, J.M. Guss, C.A. Collyer, W.A. Denny and L.P. Wakelin. Crystal structure of the topoisomerase II poison 9-amino-[N-(2-dimethylamino)ethyl]acridine-4-carboxamide bound to the DNA hexanucleotide d(CGTACG)2, Biochemistry 38 (1999) 9221-9233. [106] J.M. Berger, S.J. Gamblin, S.C. Harrison and J.C. Wang. Structure and mechanism of DNA topoisomerase II, Nature 379 (1996) 225-232. [107] M.E. Shea and H. Hiasa. Distinct effects of the UvrD helicase on topoisomerase-quinolone-DNA ternary complexes, J Biol Chem 275 (2000) 14649-14658. [108] M.T. Howard, S.H. Neece, S.W. Matson and K.N. Kreuzer. Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase, Proc Natl Acad Sci U S A 91 (1994) 12031-12035. [109] P. D'Arpa, C. Beardmore and L.F. Liu. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons, Cancer Res 50 (1990) 6919-6924. [110] H. Hiasa, D.O. Yousef and K.J. Marians. DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone-DNA ternary complex, J Biol Chem 271 (1996) 26424-26429. [111] H. Xiao, Y. Mao, S.D. Desai, N. Zhou, C.Y. Ting, J. Hwang and L.F. Liu. The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway, Proc Natl Acad Sci U S A 100 (2003) 3239-3244. [112] Y. Mao, S.D. Desai, C.Y. Ting, J. Hwang and L.F. Liu. 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes, J Biol Chem 276 (2001) 40652-40658. [113] A. Zhang, Y.L. Lyu, C.P. Lin, N. Zhou, A.M. Azarova, L.M. Wood and L.F. Liu. A protease pathway for the repair of topoisomerase II-DNA covalent complexes, J Biol Chem 281 (2006) 35997-36003. [114] P. Daroui, S.D. Desai, T.K. Li, A.A. Liu and L.F. Liu. Hydrogen peroxide induces topoisomerase I-mediated DNA damage and cell death, J Biol Chem 279 (2004) 14587-14594. [115] D. Subramanian, E. Kraut, A. Staubus, D.C. Young and M.T. Muller. Analysis of topoisomerase I/DNA complexes in patients administered topotecan, Cancer Res 55 (1995) 2097-2103. [116] H. Xiao and D.W. Goodrich. The retinoblastoma tumor suppressor protein is required for efficient processing and repair of trapped topoisomerase II-DNA-cleavable complexes, Oncogene 24 (2005) 8105-8113. [117] P. Zhang, W. Gao, H. Li, E. Reed and F. Chen. Inducible degradation of checkpoint kinase 2 links to cisplatin-induced resistance in ovarian cancer cells, Biochem Biophys Res Commun 328 (2005) 567-572. [118] C.H. Huang, C.K. Mirabelli, Y. Jan and S.T. Crooke. Single-strand and double-strand deoxyribonucleic acid breaks produced by several bleomycin analogues, Biochemistry 20 (1981) 233-238. [119] M. Malik, K.C. Nitiss, V. Enriquez-Rios and J.L. Nitiss. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage, Mol Cancer Ther 5 (2006) 1405-1414. [120] T. Andoh and R. Ishida. Catalytic inhibitors of DNA topoisomerase II, Biochim Biophys Acta 1400 (1998) 155-171. [121] J.W. Han, C.A. Dionne, N.L. Kedersha and V.S. Goldmacher. p53 status affects the rate of the onset but not the overall extent of doxorubicin-induced cell death in rat-1 fibroblasts constitutively expressing c-Myc, Cancer Res 57 (1997) 176-182. [122] T. Thompson, C. Tovar, H. Yang, D. Carvajal, B.T. Vu, Q. Xu, G.M. Wahl, D.C. Heimbrook and L.T. Vassilev. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis, J Biol Chem 279 (2004) 53015-53022. [123] J.M. Brown and B.G. Wouters. Apoptosis, p53, and tumor cell sensitivity to anticancer agents, Cancer Res 59 (1999) 1391-1399. [124] W.J. Slichenmyer, W.G. Nelson, R.J. Slebos and M.B. Kastan. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage, Cancer Res 53 (1993) 4164-4168. [125] B.B. Zhou and S.J. Elledge. The DNA damage response: putting checkpoints in perspective, Nature 408 (2000) 433-439. [126] T.K. Li, P.J. Houghton, S.D. Desai, P. Daroui, A.A. Liu, E.S. Hars, A.L. Ruchelman, E.J. LaVoie and L.F. Liu. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug, Cancer Res 63 (2003) 8400-8407. [127] S.D. Desai, T.K. Li, A. Rodriguez-Bauman, E.H. Rubin and L.F. Liu. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells, Cancer Res 61 (2001) 5926-5932. [128] D.C. Dartsch and F. Gieseler. Repair of idarubicin-induced DNA damage: A cause of resistance?, DNA Repair (Amst) 6 (2007) 1618-1628. [129] J.S. Coon, E. Marcus, S. Gupta-Burt, S. Seelig, K. Jacobson, S. Chen, V. Renta, G. Fronda and H.D. Preisler. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer, Clin Cancer Res 8 (2002) 1061-1067. [130] M.R. Lieber, Y. Ma, U. Pannicke and K. Schwarz. Mechanism and regulation of human non-homologous DNA end-joining, Nat Rev Mol Cell Biol 4 (2003) 712-720. [131] P.D. Aplan. Chromosomal translocations involving the MLL gene: molecular mechanisms, DNA Repair (Amst) 5 (2006) 1265-1272. [132] M.A. Osley. Transcription RINGs in repair, Nat Cell Biol 7 (2005) 553-555. [133] Y. Takagi, C.A. Masuda, W.H. Chang, H. Komori, D. Wang, T. Hunter, C.A. Joazeiro and R.D. Kornberg. Ubiquitin ligase activity of TFIIH and the transcriptional response to DNA damage, Mol Cell 18 (2005) 237-243. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38060 | - |
dc.description.abstract | DNA拓樸異構酶在各類生物體都廣泛存在,功能卻又獨特奇妙,隨著演化長河的蛻變,負責起解決伴隨DNA複製、轉錄、重組、修復時應運而生的各式拓樸問題。它們能舒展DNA超螺旋體的緊密結構,也能拆解DNA鎖鏈。作用機制是利用酵素活性中心區域的酪氨酸,與DNA的磷酸根之間形成的磷酸酪氨酸鍵結 (phosphotyrosyl bond),來切割繼而黏合DNA組成份的磷酸二酯鍵 (phosphodiester bond)。人類細胞中,至今發現一共有六種DNA拓樸異構酶,分別為核內的第一型拓樸異構酶、第二型拓樸異構酶α及β同質異構體、第三型拓樸異構酶α及β同質異構體,另外還有粒腺體拓樸異構酶。這些成員生物功能仍未盡知悉,例如最新發現的第三型拓樸異構酶,就還未知功能。另一方面,基於第一型和第二型拓樸異構酶的「DNA剪裁特性」,已經使它們成功被開發為癌症治療藥物的分子標靶。然而關於藥物專一性、療效的探討,與臨床副作用的衍生問題仍待解決。因此在本論文,先於第一章概述拓樸異構酶運行的奇妙宇宙:舉凡DNA超螺旋的起源、調控、維護及平衡,到拓樸異構酶的分類、功能與治療性應用,一一做文獻回顧。接著,我的研究欲進一步對這巧妙的DNA魔術師,掀開它光明與黑暗面的神秘面紗。第二章中,即敘述我們發現了人類第三型拓樸異構酶α同質異構體,具備維護染色質結構暨基因體穩定性的角色。這項發現,開展了探索這位拓樸異構酶家族新成員的生理及抑癌功能之重要面向。我們也在第三章的研究中發現,細胞處理過程會參與活化藉由第二型拓樸異構酶造成的DNA損傷反應。其中DNA複製、轉錄與蛋白酶體,是處理第二型拓樸異構酶造成的DNA損傷必需的三項細胞活動;它們也繼而為此DNA損傷反應開啟的下游反應,像是偵測、修復DNA損傷、或死亡程式所必需。最後,第四章中總結本論文,且提供後續研究之展望。 | zh_TW |
dc.description.abstract | DNA topoisomerases are ubiquitous, yet magical enzymes that are evolved to solve the topological problems on DNA generated during replication, transcription, recombination and repair. They can relax and/or decatenate DNA by transesterification reaction involving cleavage and religation of DNA phosphodiester bond via active center phosphotyrosyl linkage between DNA and enzyme. In human cells, there are six topoisomerases known to date: nuclear topoisomerase I, topoisomerases IIα and IIβ, topoisomerases IIIα and IIIβ,as well as mitochondria topoisomerase I .The biological roles of many of these members, for example the newly identified topoisomerases IIIα and IIIβ, are still unknown. On the other hand, topoisomerases I and II have been developed as molecular targets of cancer drugs due to their scissoring action on DNA. Nevertheless, many problems remain to be solved regarding the drug selectivity, potency and clinical side effects. In this dissertation, the magic topoisomerase world, including the origin, regulation and maintenance/homeostatic of DNA supercoiling, DNA topoisomerases and their therapeutic implications, is generally reviewed in chapter I. In addition, my studies were intended to expand and offer greater insights into understanding both the bright- and dark-side of this elegant, yet mysterious DNA magician. We uncovered “the roles of human topoisomerase IIIα in chromatin structure and genome stability” in chapter II, which opened up very important aspects about the biological and tumorigenic roles of a young topoisomerase family member. In chapter III, we revealed that “cellular processing pathways contribute to the activation of topoisomerase II-mediated DNA damage responses“. Three cellular activities, replication, transcription and proteasome are required for processing topoisomerase II-linked DNA breakage for initiating downstream DNA damage detection, repair as well as cell death programs. Finally, the conclusion and prospective about this study would be provided in chapter IV. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T15:59:23Z (GMT). No. of bitstreams: 1 ntu-97-D92445004-1.pdf: 2087815 bytes, checksum: 449eae3611586a8a3bd639e40b8d32ad (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 論文口試委員審定書 ………………………………………………………… i
中文摘要 ……………………………………………………………………… ii Abstract ……………………………………………………………………… iii Contents ……………………………………………………………………… v Chapter I The magic world of topoisomerases: an overview ………………… 1 1.DNA topology and structure ..................................................................... 2 Defining DNA topology by mathematic mean …………………………… 2 Multiple DNA topological states in biology ............................................... 4 2.DNA topoisomerase: the unique family of regulators for DNA topology …6 Type I DNA topoisomerase ……………………………………………… 7 Type II DNA topoisomerase ……………………………………………… 8 3. Topoisomerase-maintained genome stability ………………………… 10 3.1. Through recombination control ………………………………………… 10 3.2. Through mitosis control ……………………………………………… 11 3.3. Through checkpoint control …………………………………………… 12 4. Topoisomerase-mediated DNA damage ………………………………… 12 4.1. Mechanism of damage …………………………………………………… 13 4.2. Cellular responses and clinical implications to topoisomerase II-targeting drugs ………………………………………… 14 Chapter II The roles of human topoisomerase IIIα in chromatin structure and genome stability ……………………………………………………………………… 16 1. Introduction ………………………………………………………… 19 2. Materials and Methods ……………………………………………… 23 2.1. Cell lines …………………………………………………………… 23 2.2. hTOP3α siRNA sequence …………………………………………… 23 2.3. Flow cytometry for DNA content and cell cycle analysis …………… 23 2.4. Mitotic spread experiment …………………………………………… 24 2.5. Nuclease digestion …………………………………………………… 24 3. Results ………………………………………………………………… 26 3.1. Establishment of hTOP3α-deficient conditions using siRNA technology .… 26 3.2. Reduced expression of cellular hTOP3α results in chromosome instability, CIN …………………………………………………………………… 26 3.3. Under-condensed chromosome/chromatin in hTOP3α-deficient cells ...... 27 3.4. Increased nuclease accessibility to both metaphase and interphase chromatin in hTOP3α-deficient cells …………………..……………………………… 28 3.5. The chromosome/chromatin under-condensation in si-hTOP3α HeLa is not due to excess single-stranded DNA on chromosome ……..…………… 29 3.6. The CIN phenotype might result from chromosome under-condensation via mis-segregation during mitosis in hTOP3α-deficient cells ................... 30 3.7. The mitotic checkpoint defect in hTOP3α-deficient cells ……………… 31 3.8. si-hTOP3α HeLa cells exhibit cancer hallmark and elevated expression/activation of AKT ……….……………………………… 32 4. Discussion ……………………………………………………………… 34 4.1. hTOP3α as a potential genome caretaker ………………………… 34 4.2. hTOP3α in chromatin structure and chromosome/chromatin condensation.34 4.3. hTOP3α involvement in mitotic checkpoint ……………………… 36 4.4. hTOP3α in tumorigenesis ……............................................................. 37 Chapter III Cellular processing pathways contribute to the activation of topoisomerase II-mediated DNA damage responses ….………………………… 38 1. Introduction …………………………………………………………… 41 2. Materials and Methods …………………………………………………. 45 2.1. Drugs, chemicals and cell culture ………………………………………. 45 2.2. Antibodies and immunoblotting analysis …………………………… 45 2.3. In vivo complex of enzyme (ICE) assay ……………………………… 46 2.4. Topoisomerasae degradation assay ……………………………………… 47 2.5. Plasmid integration assay ……………………………………………… 48 2.6. Cytotoxicity assays --- MTT analysis and colony formation assay …….. 49 2.7. Quantitative measurement and statistic analysis ……………………… 49 3. Results ………………………………………………………51 3.1. Etoposide traps covalent TOP2-DNA complex (TOP2cc) in cells ……… 51 3.2. Proteasome-mediated and transcription-dependent degradation of TOP2α and TOP2β upon etoposide treatment in cancer cells ……………………… 51 3.3. Downregulation of TOP2 upon etoposide treatment is associated with TOP2cc ………………………………………………………………… 52 3.4. Proteasome-mediated downregulation of TOP2 is involved in the activation of etoposide-induced phosphorylations of Chk1, Chk2, RPA and H2AX ….53 3.5. Transcription contributes to etoposide-activated DNA damage signals with a similar spectrum to that mediated by proteasome ………………………..55 3.6. Replication-initiated processing (RIP) plays a distinct role from TIP in activation of etoposide-induced DNA damage signals: the phosphorylations of p53, RPA and H2AX …………………………………………….. 56 3.7. TIP and RIP pathways are specifically required for TOP2-capped DNA breaks, but not for bleomycin-induced DNA breaks ………………… 56 3.8. Modulation of etoposide-induced non-homologous end joining (NHEJ) by active replication, transcription or proteasome ……………………… 57 3.9. TIP and RIP contribute distinctively to etoposide-induced cell killing …. 58 3.10. APH pre-treatment protects HCT116 cells from etopoisde-induced cell death in a p53-dependent manner ……………………………………… 59 4. Discussion …………………………………………………… 61 4.1. Cellular processing pathways contribute to TOP2cc-mediated damage responses …………………………………… 61 4.2.Proteolysis removal of TOP2αcc ……………………………… 62 4.3.TOP2cc, cellular processing pathways, tumor cell killing and therapy-related secondary leukemia …………………………………………… 63 Chapter IV Conclusion and perspective ……………………… 65 Figures ………………………………………………………… 69 References ……………………………………………………… 103 Appendix : curriculum vitae ………………………………… 113 | |
dc.language.iso | en | |
dc.title | 人類DNA拓樸異構酶在基因體損傷及穩定性之功能探討 | zh_TW |
dc.title | Study on the Roles of Human Topoisomerases in DNA Damage and Chromosome Stability | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 陳振陽,王萬波,鄧述諄,詹迺立 | |
dc.subject.keyword | DNA拓樸異構酶,DNA損傷反應,蛋白酶,體,染色質結構,基因穩定性, | zh_TW |
dc.subject.keyword | DNA topoisomerase,cleavable complex,DNA damage response,proteasome degradation,chromatin structure,genome stability, | en |
dc.relation.page | 114 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2008-05-08 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 2.04 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。